Hi all .. If memory serves me correctly. None of these patients would have qualified to be a part of any specific trial. Their health situation was not suitable- from my understanding. So taking that into consideration, if I am correct, this result is more than -outstanding.
Thinking:- from my reads and research- you do your own- I may be a little off track here.
-no more open heart surgery - maybe less costs ?
-no long delay in hospital beds- A real positive benefit for the health system.
-less danger of infection - only a small wound (near groin ????)
-seemed to me some (or all) patients felt much better in a very short time after procedure (close to immediately ???) Better blood flow.
-for use in younger patients
-Not sure if any medicine - tablets are necessary after procedure - for extended period.
-If necessary- way down track -another procedure can be performed.
- May be others I missed
Keep safe all - lots of interesting news to come.
- Forums
- ASX - By Stock
- Ann: DurAVR First in Human Study 12 Month Results
AVR
anteris technologies global corp.
Add to My Watchlist
0.49%
!
$6.12

Hi all .. If memory serves me correctly. None of these patients...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$6.12 |
Change
-0.030(0.49%) |
Mkt cap ! $94.85M |
Open | High | Low | Value | Volume |
$6.21 | $6.21 | $6.00 | $16.53K | 2.704K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | $6.01 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$6.08 | 240 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1000 | 6.010 |
2 | 1624 | 6.000 |
1 | 25 | 5.850 |
1 | 857 | 5.830 |
1 | 900 | 5.780 |
Price($) | Vol. | No. |
---|---|---|
6.080 | 240 | 1 |
6.180 | 50 | 1 |
6.190 | 1000 | 1 |
6.200 | 1000 | 1 |
6.400 | 130 | 1 |
Last trade - 15.46pm 25/06/2025 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
SPONSORED BY The Market Online